218594-00-4

Basic information

• Product Name: 4 - ForMyl - 1 - (triphenylMethyl)pyrazole
• Synonyms: 4 - ForMyl - 1 - (triphenylMethyl)pyrazole;1-Trityl-1H-pyrazole-4-carbaldehyde;1-(Triphenylmethyl)-1H-pyrazole-4-carboxaldehyde
• CAS NO: 218594-00-4
• Molecular Formula: C₂₃H₁₈N₂O
• Molecular Weight: 338.40182
• Mol File: 218594-00-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4 - ForMyl - 1 - (triphenylMethyl)pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4 - ForMyl - 1 - (triphenylMethyl)pyrazole(218594-00-4)
• EPA Substance Registry System: 4 - ForMyl - 1 - (triphenylMethyl)pyrazole(218594-00-4)

Safety Data

• Hazardous Substances Data: 218594-00-4(Hazardous Substances Data)

Upstream product

• 76-83-5 trityl chloride 
• 35344-95-7 1H-pyrazole-4-carbaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 191980-54-8 4-iodo-1-(triphenylmethyl)-1H-pyrazole 

Downstream Products

• 1031351-90-2 1-{[(1-trityl-1H-pyrazol-4-yl)methyl]amino}butan-2-ol 
• 226989-36-2 4-hydroxy-1-trityl-1H-pyrazole 
• 1326316-28-2 3-allyl-4-hydroxy-1-trityl-1H-pyrazole 
• 218592-67-7 (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-(4-pyrazolylmethyl)piperazine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Divergent synthesis and evaluation of inhibitory activities against cyclooxygenases-1 and -2 of natural withasomnines and analogues

The divergent synthesis of natural withasomnines and analogues was achieved from 4-hydroxypyrazoles, which was prepared via alkaline hydrolysis of the Baeyer-Villiger oxidation products from 4-formylpyrazoles. Key steps of this synthesis are regioselective Claisen rearrangement of 4-allyloxypyrazoles and the Suzuki-Miyaura coupling of 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl trifluoromethanesulfonate and commercially available arylboronic acids. The Suzuki-Miyaura coupling at the final step of this strategy enabled facile access to natural withasomnines and their analogues. The biological activities of the twelve synthesized compounds against cyclooxygenases-1 and -2 (COX-1 and COX-2) were evaluated.